Stockreport

Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas

Affimed N.V.  (AFMD) 
Last affimed n.v. earnings: 11/19 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: affimed.com/investor-relations.php
PDF Data Demonstrate AFM13 in Combination with Keytruda® (Pembrolizumab) Doubled Complete Response Rate in Hodgkin Lymphoma Patients Early Data Suggest New Opportunity f [Read more]